Anti-Alpha Synuclein Antibody

Alpha-Synuclein

Shipped on ice packs

18 kDa

24 months from date of receipt

Human

Alpha-synuclein (SNCA), also known as PARK1, NACP, PARK4, is a member of the synuclein family, which also includes beta- and gamma-synuclein. Alpha-synuclein is a highly conserved protein known to be abundant in neurons and especially presynaptic terminals where it serves multiple roles including regulation of synaptic vesicle trafficking and subsequent neurotransmitter release. Functionally, alpha-synuclein has been implicated in synaptic plasticity (Liu 2004) and the assembly of snare complexes (Burre 2010) and it is known to be associated with various neuropathologies including Parkinson's Disease, Lewy Body Dementia, and Alzheimer's Disease, where it forms insoluble protein aggregates. Early studies of amyloid deposits in the brains of Alzheimer's patients revealed two previously uncharacterized peptides in addition to the amyloid beta fragment (Ueda 1993), both of which were found to correspond to alpha-synuclein (SNCA). Later studies confirmed that aggregated alpha-synuclein proteins are present in brain lesions (Lewy bodies) that are hallmarks of neurodegenerative synucleinopathies and that alpha-synuclein likely plays a role in the pathogenesis of Parkinson's disease, Lewy body dementia, and Alzheimer’s disease among other neuropathologies. The SNCA antibody was raised against full-length human alpha-synuclein and recognizes endogenous levels of alpha-synuclein in brain by Western blot and immunohistochemistry.

No cross-reactivity reported

Purified by Protein A Chromatography

Produced by in vitro bioreactor culture of hybridoma line followed by Protein A affinity chromatography. Purified mAbs are >90% specific antibody.

WB Brain

1:5000

These antibodies are to be used as research laboratory reagents and are not for use as diagnostic or therapeutic reagents in humans.